ScholarLens Back to search
2001•Fujian Yike Daxue xuebaoRequires access

Adriamycin and its Synergistic Cytotoxicity with Verapamil Against OS732 in vitro

Lin Jian

Open publisher page 0 citations

Abstract

Objective To evaluate the activity and synergistic cytotoxicity of adriamycin in combination with verapamil to OS732 tumor cell in vitro. Methods The activity of adriamycin with different grades concenstration and its synergistic cytoxicity with verapamil to OS732 after 24 h, 48 h and 72 h culture were surveyed by colorimetric MTT test. The CD95 level was detected by FCM. Results The cytotoxicity of adriamycin against OS732 has a dose\|dependant relation, but its cytotoxicity doesn't increase equally as the time elapsed. Verapamil with a dose without any cytotoxicity also can enhance the cytotoxicity of adriamycin and increase the expression level of CD95. Conclusion The mechanism of verapamil to adriamycin in OS732 may be differs from its reverse effect to multidrug resistance.

About this research paper

What this paper is about

Objective To evaluate the activity and synergistic cytotoxicity of adriamycin in combination with verapamil to OS732 tumor cell in vitro. Methods The activity of adriamycin with different grades concenstration and its synergistic cytoxicity with verapamil to OS732 after 24 h, 48 h and 72 h culture were surveyed by colorimetric MTT test. The CD95 level was detected by FCM. Results The cytotoxicity of adriamycin against OS732 has a dose\|dependant relation, but its cytotoxicity doesn't increase equally as the time elapsed. Verapamil with a dose without any cytotoxicity also can enhance the cytotoxicity of adriamycin and increase the expression level of CD95. Conclusion The mechanism of verapamil to adriamycin in OS732 may be differs from its reverse effect to multidrug resistance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the activity and synergistic cytotoxicity of adriamycin in combination with verapamil to OS732 tumor cell in vitro. Methods The activity of adriamycin with different grades concenstration and its synergistic cytoxicity with verapamil to OS732 after 24 h, 48 h and 72 h culture were surveyed by colorimetric MTT test. The CD95 level was detected by FCM. Results The cytotoxicity of adriamycin against OS732 has a dose\|dependant relation, but its cytotoxicity doesn't increase equally as the time elapsed. Verapamil with a dose without any cytotoxicity also can enhance the cytotoxicity of adriamycin and increase the expression level of CD95. Conclusion The mechanism of verapamil to adriamycin in OS732 may be differs from its reverse effect to multidrug resistance.

Key concepts: Verapamil, Cytotoxicity, Pharmacology, In vitro, MTT assay, Chemistry, Efflux, Multiple drug resistance

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Adriamycin and its Synergistic Cytotoxicity with Verapamil Against OS732 in vitro — Research Paper | ScholarLens